| Biomarker ID | 1586 |
| PMID | 25307116 |
| Year | 2014 |
| Biomarker | AF087978; uc002llc; EF177379; BC013821; uc001pyz; AK024556; AB116553; BC012900; LOC100506303; LOC100506922y; LOC100287482; XLOC_l2_009441; LOC154822; XLOC_010807; XLOC_002335; XLOC_l2_009136; XLOC_002871; ANKRD20A9Py; FLJ20444; XLOC_003734y; LOC100505666; LOC100506411; XLOC_007697; XLOC_003734y; XLOC_l2_000735; LOC100129480; XLOC_007162; LOC100506802; LOC100507025; XLOC_010813; |
| Biomarker Basis | Expression Based |
| Biomolecule | LncRNA |
| Source | Cell Lines |
| Subjects | Humans |
| Regulation | Upregulated in PC3 (Log Fold Change) [AF087978 (5.8 fold) ; uc002llc(4.8 fold) ; EF177379(4.3 fold) ; BC01382(3.8 fold)1 ; uc001pyz(3.7 fold) ; AK024556 (3.7 fold) ; AB116553 (3.5 fold) ; BC012900 (3.5 fold) ; LOC100506303(2.6 fold) ; LOC100506922(3.6 fold); LOC100287482 (3.0 fold); XLOC_l2_009441 (3.3 fold); LOC154822 (3.2 fold) ; XLOC_010807(3.5 fold) ; XLOC_002335 (3.4 fold); XLOC_l2_009136(2.1 fold); XLOC_002871 (2.3 fold); ANKRD20A9P ( 2.0 fold) ; FLJ20444 (4.1 fold); XLOC_003734( 4.0 fold); LOC100505666(2.1 fold); LOC100506411(4.1 fold); XLOC_007697(3.4 fold); XLOC_003734y(3.5 fold) XLOC_l2_000735(4.6 fold); LOC100129480(4.5 fold); XLOC_007162(3.1 fold); LOC100506802(3.4 fold); LOC100507025(5.7 fold); XLOC_010813(3.8 fold;] |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | NA |
| Experiment | PC3 Cells Vs prostate epithelial cells |
| Type of Biomarker | Diagnostic |
| Cohort | EP, prostate epithelial cells, LNCap and PC3 cells were used for the experiment |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p<0.05 |
| Method Used | Microarrays |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Validation on human patient cohort |
| Technical Name | NA |